Table 4.
Univariate and multivariate analyses of risk factors for PFS of FP and RP.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p-value | HR | 95%CI | p-value | |
| Age | ||||||
| ≥65 vs <65 | 1.05 | 0.47-2.36 | 0.905 | |||
| Sex | ||||||
| female vs male | 1.19 | 0.44-3.22 | 0.726 | |||
| ECOG PS | ||||||
| 0 vs 1 vs 2 | 2.37 | 1.21-4.66 | 0.012 | 2.18 | 1.05-4.54 | 0.037 |
| Tumor location | ||||||
| left vs right | 1.43 | 0.53-3.85 | 0.478 | |||
| Site of primary tumor | ||||||
| rectum vs colon | 0.83 | 0.37-1.87 | 0.649 | |||
| Liver metastasis | ||||||
| yes vs no | 2.00 | 0.85-4.69 | 0.112 | |||
| Lung metastases | ||||||
| yes vs no | 1.11 | 0.47-2.63 | 0.815 | |||
| Peritoneal metastases | ||||||
| yes vs no | 1.42 | 0.51-3.97 | 0.500 | |||
| Number of distant metastatic sites | ||||||
| ≥3 vs <3 | 1.48 | 0.66-3.31 | 0.343 | |||
| KRAS or NRAS mutation | ||||||
| yes vs no | 1.61 | 0.63-4.08 | 0.318 | |||
| BRAF mutation | ||||||
| yes vs no | 0.73 | 0.10-5.51 | 0.762 | |||
| Prior antitumor treatment | ||||||
| surgery vs chemotherapy or radiation therapy | 0.66 | 0.26-1.67 | 0.379 | |||
| Targeted drugs | ||||||
| fruquintinib vs regorafenib | 2.52 | 1.10-5.76 | 0.028 | 3.05 | 1.26-7.38 | 0.014 |
| Previous anti-VEGF treatment | ||||||
| yes vs no | 2.72 | 0.89-8.34 | 0.080 | 3.62 | 1.17-11.23 | 0.026 |
| Previous anti-EGFR treatment | ||||||
| yes vs no | 2.40 | 1.00-5.77 | 0.051 | 2.12 | 0.88-5.08 | 0.093 |
ECOG PS, Eastern Cooperative Oncology Group performance status; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor.
The bold value in the univariate analysis represents p<0.1 and is included in the multivariate analysis; The bold values in multivariate analysis represent p<0.05, and the difference is statistically significant.